Prostatype Genomics AB (publ) (PROGEN.ST)
SEK 2.15
(12.57%)
SEK 2.15
(12.57%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -38.02 Million SEK | -39.74% |
| 2022 | -26.78 Million SEK | -73.26% |
| 2021 | -15.45 Million SEK | 6.13% |
| 2020 | -15.76 Million SEK | 0.0% |
| 2018 | -7.7 Million SEK | 14.04% |
| 2017 | -8.96 Million SEK | -98.42% |
| 2016 | -4.51 Million SEK | 59.95% |
| 2015 | -11.28 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -9.69 Million SEK | 0.0% |
| 2024 Q1 | -9.69 Million SEK | 5.22% |
| 2023 Q1 | -7.32 Million SEK | 4.56% |
| 2023 FY | - SEK | -39.74% |
| 2023 Q2 | -9.58 Million SEK | -30.92% |
| 2023 Q3 | -10.23 Million SEK | -6.7% |
| 2023 Q4 | -10.23 Million SEK | 0.0% |
| 2022 FY | - SEK | -73.26% |
| 2022 Q4 | -7.67 Million SEK | -6.94% |
| 2022 Q3 | -7.17 Million SEK | -4.2% |
| 2022 Q2 | -6.88 Million SEK | -36.35% |
| 2022 Q1 | -5.05 Million SEK | 11.57% |
| 2021 Q1 | -3.37 Million SEK | 13.8% |
| 2021 FY | - SEK | 6.13% |
| 2021 Q4 | -5.71 Million SEK | -58.06% |
| 2021 Q3 | -3.61 Million SEK | -55.2% |
| 2021 Q2 | -2.32 Million SEK | 30.96% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q4 | -3.91 Million SEK | -10.03% |
| 2020 Q3 | -3.55 Million SEK | -14.22% |
| 2020 Q2 | -3.11 Million SEK | -98.1% |
| 2020 Q1 | -1.57 Million SEK | 13.03% |
| 2019 Q4 | -1.8 Million SEK | -82.92% |
| 2019 Q3 | -987.7 Thousand SEK | 0.0% |
| 2018 FY | - SEK | 14.04% |
| 2017 FY | - SEK | -98.42% |
| 2016 FY | - SEK | 59.95% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AroCell AB (publ) | -13.75 Million SEK | -176.328% |
| Devyser Diagnostics AB (publ) | -43.8 Million SEK | 13.196% |
| Immunovia AB (publ) | -166.55 Million SEK | 77.173% |
| SenzaGen AB | -13.53 Million SEK | -180.881% |
| Spermosens AB | -10.7 Million SEK | -255.194% |